---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-008044"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:20:42.089081+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia

## Summary
- BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
- CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.
- VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.
- Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.
- Conditions include IP license agreement; other definitive agreements not yet executed.

## SEC filing metadata
- accession: 0001477932-25-008044
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/0001477932-25-008044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-008044
- JSON: https://secwatch.observer/filing/0001477932-25-008044.json
- Plain text: https://secwatch.observer/filing/0001477932-25-008044.txt

## Key facts
- Equity Issuances
  BioNexus Gene Lab Corp issued restricted shares representing 19.9% of its outstanding common stock of common stock to Fidelion Diagnostics Pte. Ltd..
  - Security: common stock
  - Shares: restricted shares representing 19.9% of its outstanding common stock
  - Purchaser: Fidelion Diagnostics Pte. Ltd.
  source text: In connection with the SSSA, upon completion the Company will issue restricted shares representing 19.9% of its outstanding common stock to Fidelion as consideration for the Company’s subscription of Fidelion shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/0001477932-25-008044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.